Clostridium difficile colitis: Factors influencing treatment failure and relapse a prospective evaluation

American Journal of Gastroenterology

Volumn 93, Issue 10, 1998, Pages 1873-1876

  Nair, Satheesh ^a   Yadav, Dhiraj ^a   Corpuz, Marilou ^a   Pitchumoni, C S ^a,b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Our Lady of Mercy Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM TOXIN; CYTOTOXIN; METRONIDAZOLE; SERUM ALBUMIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE; COLITIS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; RISK FACTOR; TREATMENT FAILURE;

AGED; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; MALE; METRONIDAZOLE; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; SERUM ALBUMIN; TIME FACTORS; TREATMENT FAILURE; VANCOMYCIN;

EID: 0032435128     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(98)00422-5     Document Type: Article

References (17)

1. 1. Fekety R, Shah A. Diagnosis and treatment of C. difficile colitis. JAMA 1993;269:71-5.
2. 2. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994;330:257-62.
3. 3. Fekety R, Silva J, Armstrong J, et al. Treatment of antibiotic-associated enterocolitis with vancomycin. Rev Infect Dis 1981;3:S273.
4. 4. Dudley MN, McLaughlin JC, Carrington G, et al. Oral bacitracin vs. vancomycin therapy for Clostridium difficile-induced diarrhea. Arch Intern Med 1986;146:1101.
5. 5. Bartlett JG, Tedesco FJ, Shull S, et al. Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology 1980;78:431.
6. 6. Walters BAJ, Roberts R, Stafford R, Seneviratne E. Relapse of antibiotic-associated colitis: Endogenous persistence of Clostridium difficile during vancomycin therapy. Gut 1983;24:206.
7. 7. Gerding DM, Brazier JS. Optimal method for identifying Clostridium difficile infections. Clin Infect Dis 1993;16:439-42.
8. 8. Barlett JG, Chang TW, Gurwith M, et al. Antibiotic associated pseudomembranous colitis due to toxin producing clostridia. N Engl J Med 1978;298:531-4.
9. 9. Rybolt AH, Bennet RG, Laughon BE. Protein losing enteropathy associated with Clostridium difficile infection. Lancet 1989;1:1353-5.
10. 10. Rothchild MA, Oratz M, Schreiber SS. Albumin synthesis. N Engl J Med 1972;286:748-57.
11. 11. Ramaswamy R, Grover H, Corpuz M, et al. Prognostic criteria in Clostridium difficile colitis. Am J Gastroenterol 1996;91:460-4.
12. 12. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile associated diarrhea and colitis. Am J Gastroenterol 1997;92: 739-40.
13. 13. Wilson K, Perini F. Role of competition for nutrients in suppression of C. difficile by colonic microflora. Infect Immun 1988;56:2610-4.
14. 14. Fekety R, Silva J, Kauffman C, et al. Treatment of antibiotic associated Clostridium difficile colitis with oral vancomycin: Comparison of two dosage regimens. Am J Med 1989;86:15-9.
15. 15. Onderdonk AB, Cisnoeros RL, Barlett JG. Clostridium difficile in gnotobiotic mice. Infect Immun 1980;28:277-82.
16. 16. Burdon DW, Brown JD, Youngs D, et al. Antibiotic susceptibility of Clostridium difficile. J Antimicrob Chemother 1979;5:307.
17. 17. Wilcox MH, Fawley WN, Settle CD, et al. Clinical recurrence of Clostridium difficile infection: Relapse or reinfection. Abstract presented at 37th ICAAC Meeting at Toronto, Canada September 28-October 1, 1997.